FDA adds rare vision-loss warning to popular GLP-1 drugs

The U.S. Food and Drug Administration is adding a warning about a rare eye condition to labeling for GLP-1 medicines, including Ozempic and Wegovy. The condition, non-arteritic anterior ischemic optic neuropathy, can reduce blood flow to the optic nerve and may cause permanent vision loss. The FDA said the warning will apply to the drug class, which is used for weight loss, diabetes and other conditions.